Interruption of natalizumab therapy for multiple sclerosis: What are the risks?

Robert T. Naismith, Dennis Bourdette

Research output: Contribution to journal › Editorial › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Interruption of natalizumab therapy for multiple sclerosis: What are the risks?'. Together they form a unique fingerprint.